Prescient Therapeutics prepares for ‘pivotal’ year of PTX-100 development to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual...
Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced continuing positive results in the PTX-100 phase 1b...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel...
Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps...
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.